A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
A recent CME course using Facebook Live generated 34,000 views and 600 comments.
The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.
Rather than overtly push product information to already-stressed parents, 2e Creative and Alcon created Muck, a gorgeous glossy magazine available alongside other magazines in pediatricians' waiting rooms.
Rising healthcare costs, the need for team health delivery and enhanced teamwork, and empowered consumers have all played a role.
One critical aspect of oncology drugmakers' business remains firmly rooted in the past. That's customer experience.
A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion